For the quarter ending 2026-03-31, ACLS had $5,379K increase in cash & cash equivalents over the period. $16,300K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | - | 238,330 | - | - |
| Cost of revenue | - | 126,398 | - | - |
| Research and development | - | 30,126 | - | - |
| Sales and marketing | - | 19,403 | - | - |
| General and administrative | - | 26,231 | - | - |
| Total other income | - | 3,846 | - | - |
| Income tax provision | - | 5,721 | - | - |
| Net income | 9,214 | 34,297 | 25,986 | 59,955 |
| Depreciation and amortization | 4,436 | 4,461 | 4,328 | 8,824 |
| Deferred income taxes | -658 | -8,941 | 2,399 | -4,155 |
| Stock-based compensation expense | 4,899 | 5,105 | 5,344 | 10,324 |
| Provision for doubtful accounts | 65 | - | - | - |
| Provision for excess and obsolete inventory | 950 | 1,265 | 883 | 1,742 |
| Accretion of discounts and premiums on short-term and long-term investments | -39 | 819 | 1,081 | 2,254 |
| Unrealized currency loss (gain) on foreign denominated transactions | -2,930 | -4,164 | -4,578 | 6,807 |
| Mark-to-market adjustment on forward exchange contracts | -479 | 1,020 | -128 | -457 |
| Accounts receivable | -5,996 | 21,333 | 8,695 | -67,459 |
| Inventories | 3,132 | 7,969 | 17,488 | 16,760 |
| Prepaid expenses and other current assets | 10,087 | 8,537 | -2,148 | -1,175 |
| Accounts payable and other current liabilities | -1,138 | 4,826 | 29,708 | -28,343 |
| Deferred revenue | 1,627 | -19,588 | -482 | -9,581 |
| Income taxes | 2,878 | 10,935 | 214 | 1,966 |
| Other assets and liabilities | 359 | 3,413 | 2,620 | 4,480 |
| Net cash provided by operating activities | 18,139 | -6,567 | 45,350 | 79,522 |
| Expenditures for property, plant and equipment and capitalized software | 1,839 | 2,335 | 2,015 | 6,945 |
| Purchases of short-term and long-term investments | 160,696 | 139,372 | 161,452 | 345,174 |
| Maturities and sales of short-term investments | 151,896 | 134,400 | 164,845 | 387,975 |
| Net cash (used in) provided by investing activities | -10,639 | -7,307 | 1,378 | 35,856 |
| Net settlement on restricted stock grants | -1,023 | -258 | -104 | -4,152 |
| Repurchase of common stock | - | 25,231 | 32,335 | 63,515 |
| Proceeds from employee stock purchase plan purchases | - | 1,213 | 0 | 1,246 |
| Principal payments on finance lease obligation | 374 | 345 | 336 | 676 |
| Net cash used in financing activities | -1,397 | -24,621 | -32,775 | -67,097 |
| Effect of exchange rate changes on cash and cash equivalents | -724 | -554 | -106 | 1,935 |
| Net increase in cash, cash equivalents and restricted cash | 5,379 | -39,049 | 13,847 | 50,216 |
| Cash, cash equivalents and restricted cash at beginning of period | 156,078 | 195,127 | 131,064 | - |
| Cash, cash equivalents and restricted cash at end of period | 161,457 | 156,078 | 195,127 | - |
AXCELIS TECHNOLOGIES INC (ACLS)
AXCELIS TECHNOLOGIES INC (ACLS)